Serinus Biosciences
Serinus Biosciences, based in New York, NY, is a biotech company focused on developing combination therapies to combat cancer treatment resistance, utilizing an AI platform informed by system biology.
Company Overview
Serinus Biosciences, formerly known as Serinus, operates in the healthcare sector, specifically within the therapeutics sub-industry. Located in New York, NY, the company is actively developing combination therapies aimed at overcoming treatment resistance in cancer. Supported by Y Combinator and other leading investors, Serinus Biosciences leverages advanced AI technology and decades of systems biology knowledge to revolutionize precision medicine. The company is in its early developmental stages and serves regions including the United States and Canada, with options for remote and partly remote operations.
Founders and Leadership
Serinus Biosciences was founded by a team of MIT PhD graduates. The company also benefits from the guidance of a scientific advisory board composed of leading academics from prestigious institutions such as the Broad Institute, Dana-Farber Cancer Institute, and the University of California, San Diego (UCSD). This esteemed group of leaders brings a wealth of expertise and experience that helps drive the company's innovative approach to cancer treatment.
AI-Driven Cancer Treatment Solutions
Serinus Biosciences employs a fully explainable AI platform, designed to uncover how cancer cells evolve to resist treatment. This AI engine leverages decades of systems biology knowledge for biological inference, enabling the identification of molecules that can counteract resistance escape routes. By combining these molecules into treatments, Serinus aims to create therapies that are not only safer and more effective but also faster to reach patients.
Y Combinator Affiliation
Serinus Biosciences was part of the Y Combinator batch S22. Y Combinator is a renowned startup accelerator that supports early-stage companies with funding, mentorship, and resources. This affiliation has provided Serinus with the necessary backing and credibility to advance its mission of overcoming cancer treatment resistance through innovative combination therapies.
Regional Operations
Serinus Biosciences operates primarily in the United States and Canada, with its headquarters located in New York, NY. The company also accommodates remote and partly remote working arrangements, reflecting its modern approach to flexible work environments. This regional flexibility allows Serinus to attract top talent and collaborate effectively with academics and experts across North America.
